Trial Search Results

2019-06 TRISCEND Study

Early feasibility study to assess safety and performance of the Edwards EVOQUE Tricuspid Valve Replacement System

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Edwards Lifesciences


  • Device: Transcatheter Tricuspid Valve Replacement




Inclusion Criteria:

   - Functional or degenerative TR moderate or greater

   - Symptomatic despite medical therapy or prior HF hospitalization from TR

   - The Local Site Heart Team determines that the patient is appropriate for transcatheter
   tricuspid valve replacement

Exclusion Criteria:

   - Tricuspid valve anatomic contraindications

   - Need for emergent or urgent surgery or any planned cardiac surgery within the next 12

   - Hemodynamic instability

   - Refractory heart failure requiring advanced intervention

   - Currently participating in another investigational study in which the patient has not
   reached a primary endpoint

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Research Nurse